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Abstract
Objectives: The goal of this study was to characterize the association of age with postoperative
mortality and need for transitional care following hepatectomy for liver metastases.
Methods: A retrospective cohort study using the Nationwide Inpatient Sample (2005–2008) was per-
formed. Patients undergoing hepatectomy for liver metastases were categorized by age as: Young (aged
<65 years); Old (aged 65–74 years), and Oldest (aged75 years). Multivariate logistic regression analyses
were performed to identify predictors of in-hospital mortality and need for transitional care (non-home
discharge).
Results: A total of 4026 patients were identified; 36.6% (n = 1475) were elderly (aged 65 years). Rates
of in-hospital mortality and non-home discharge increased with advancing age group [1.3% vs. 2.2% vs.
3.3% (P = 0.005) and 2.1% vs. 6.1% vs. 18.3% (P < 0.001), respectively]. Independent predictors of
in-hospital mortality were age within the Oldest category [odds ratio (OR) 2.21, 95% confidence interval
(CI) 1.19–4.12] and a Deyo Comorbidity Index score of 3 (OR 6.95, 95% CI 3.55–13.60). Independent
predictors for need for transitional care were age within the Old group (OR 2.44, 95% CI 1.66–3.58), age
within the Oldest group (OR 8.48, 95% CI 5.87–12.24), a Deyo score of 1 (OR 2.00, 95% CI 1.40–2.85),
a Deyo score of 2 (OR 4.70, 95% CI 2.93–7.56), a Deyo score of 3 (OR 6.41, 95% CI 3.67–11.20), and
female gender (OR 1.56, 95% CI 1.15–2.11).
Conclusions: Although increasing age was associated with higher risk for in-hospital mortality, the
absolute risk was low and within accepted ranges, and comorbidity was the primary driver of mortality.
Conversely, need for transitional care was significantly more common in elderly patients. Therefore, liver
resection for metastases is safe in well-selected elderly patients, although consideration should be made
for potential transitional care needs.
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Introduction
The liver is the most common site of metastatic disease.1,2 Because
of the liver’s dual circulation (portal and systemic blood supplies),
primary tumours that metastasize to the liver typically originate
from the gastrointestinal tract, most frequently from the colon,
rectum or pancreas (including neuroendocrine tumours), among
other sites.3 Up to 50% of patients with these tumours are diag-
nosed with metastatic liver disease, either at initial presentation or
later during the course of their disease.4 Although a multidiscipli-
nary approach to the treatment of liver metastases is important for
accomplishing optimal and comprehensive cancer care, surgical
resection remains the only treatment with curative potential. For
patients with colorectal liver metastases, medical treatment with
systemic chemotherapy usually results in 5-year survival rates of <
5%, compared with overall survival rates of close to 60% following
liver resection.5,6 Likewise, in well-selected patients presenting with
metastatic neuroendocrine tumours to the liver, liver resection
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results in higher survival than does medical therapy or non-
operative, liver-directed interventions.7–9 Similar results have been
reported in well-selected patients treated with liver resection for
metastatic disease originating from a variety of other primary
tumour sites.10,11 In tandem with improved longterm outcomes
following hepatectomy, reports from national registries and high-
volume centres emphasize the unquestionable improvement in the
safety of hepatectomy that has occurred over the last decades;
currently, mortality is reported to be < 5%12–15 and major compli-
cations are relatively uncommon and typically temporary in
nature.12,14,15
Despite these encouraging findings, the role of surgery in liver
metastases in elderly patients has not been clearly defined.16
Given that cancer is a disease that predominantly affects elderly
people,17 and in view of the expected sustained growth of this
segment of the population, the proportion of patients with liver
metastases aged > 65 years will continue to increase and surgical
treatment – hepatectomy – should be part of the armamen-
tarium for the optimal management of their disease.16,18
Although this approach appears to be relatively intuitive, elderly
patients presenting with liver metastases are often undertreated
compared with younger adults;19,20 this difference is often driven
by providers’ unsubstantiated perceptions of worse overall out-
comes, as a result of which less aggressive diagnostic and treat-
ment strategies are offered to older patients.16 This treatment
disparity occurs despite multiple studies reporting acceptable
short-term outcomes following hepatectomy in well-selected
elderly patients.18,21–27 A major limitation of such studies,
however, is that, in most cases, they represent practices within
highly specialized centres, and their findings may not be appli-
cable to other institutions. Furthermore, these studies primarily
focus on postoperative mortality and complications, and thus
information on the effects of liver resection on transitional out-
comes in elderly patients, such as outcomes following the imme-
diate postoperative period that represent recovery to premorbid
status and quality of life following surgery, is limited. Transi-
tional outcomes are particularly relevant in elderly patients, and
postoperative and survival outcomes represent only a compo-
nent of the overall treatment goals; elderly patients already have
a shorter life expectancy as a result of their advanced age and
associated comorbidities, and thus timely recovery and subse-
quent quality of life are relatively more important.16,28
In view of these considerations, it is unclear which elderly
patients are more likely to benefit from hepatectomy in terms of
postoperative and transitional outcomes following surgery. The
goal of this study was to use a national database to better under-
stand and characterize the association of increasing age with post-
operative mortality and transitional outcomes following resection
of secondary hepatic malignancies. Specifically, this study hypoth-
esized that increased age would be associated with adverse out-
comes after hepatic resection, but that age alone would not predict
increased in-hospital mortality or need for transitional care
postoperatively.
Materials and methods
Data source: Nationwide Inpatient Sample
The Nationwide Inpatient Sample (NIS) database represents
approximately 20% of all community hospital discharges in the
USA. It is part of the Healthcare Cost and Utilization Project,
sponsored by the Agency for Healthcare Research and Quality.
The NIS database incorporates over 8 million hospital stays annu-
ally and includes data on hospital and clinical information typi-
cally found in hospital discharge abstracts, thus allowing the
analysis of nationwide trends in health care utilization, quality
and outcomes. The NIS database was purchased for the years
2005–2008 from the Healthcare Cost and Utilization Project
Central Distributor after a standard data use agreement had been
completed. Data were analysed to evaluate outcomes after hepa-
tectomy for metastatic disease in different groups of patients of
increasing age.
Study sample and data collection
The NIS database was queried for all patients who underwent liver
resection, using the International Classification of Disease, 9th
Revision, Clinical Modification (ICD-9-CM) procedure codes
50.22 (partial hepatectomy/wedge resection of liver) and 50.3
(lobectomy or extended lobectomy of liver). Using a validated
diagnostic algorithm, the study sample was limited to subjects
with a diagnosis of liver metastases.29
Patient demographic information, including age and gender,
was identified and recorded. Comorbidity was scored using the
Deyo modification of the Charlson Comorbidity Index,30 a
weighted index using ICD-9-CM diagnosis codes to define the
overall extent of each patient’s comorbidity, including the fol-
lowing diagnoses: myocardial infarction; congestive heart failure;
peripheral vascular disease; cerebrovascular disease; dementia;
chronic pulmonary disease; connective tissue disease; ulcer
disease; liver disease; diabetes; hemiplegia; renal disease; malig-
nancy, and acquired immunodeficiency syndrome (AIDS). Simi-
larly to previous studies,12 cancer diagnosis and metastases were
not included in the calculation of the score because these two
factors were present in all patients and accounted for during the
selection of the study sample. The sample was then categorized
into four groups according to the severity of comorbidities
(Deyo scores of 0, 1, 2 and 3, respectively). The sample was
also categorized into two groups according to the extent of the
hepatic resection using ICD-9-CM procedure codes for wedge
resection (code 50.22), or lobectomy or extended lobectomy
(code 50.3). Similarly, outcomes data on in-hospital mortality,
length of stay (LoS) and discharge destination were identified
and recorded.
Statistical analysis
The primary outcomes of interest were in-hospital mortality and
poor transitional outcome, defined as the need for transi-
tional care. Discharge destination was used as a surrogate for
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transitional outcome; patients discharged to a destination other
than home (i.e. non-home disposition: rehabilitation, skilled
nursing or longterm care facility) were considered to need tran-
sitional care. Secondary outcomes included LoS following hepa-
tectomy. The independent variable of interest was age; patients
were categorized into three different age groups: Young (aged <
65 years); Old (aged 65–74 years), and Oldest (aged 75 years).
Baseline patient and treatment characteristics and outcomes
were compared for the three groups, using the chi-squared test
for categorical variables and Student’s t-test for continuous vari-
ables. Multivariate logistic regression analyses were performed to
identify independent predictors of each primary outcome and to
examine the effect of increasing age while adjusting for other
important variables.
Summary statistics are presented as proportions for categorical
variables and as medians and ranges for continuous variables.
Univariate comparisons of baseline and treatment characteristics
and outcomes are reported using the P-value. Results of the mul-
tivariate models are presented as odds ratios (ORs) with corre-
sponding 95% confidence intervals (CIs) and P-values. In all
cases, a P-value of < 0.05 was considered to indicate statistical
significance. All statistical analyses were performed using spss
Statistics Version 17.0.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 4026 patients who underwent hepatectomy for liver
metastases were identified. Baseline patient and treatment char-
acteristics are shown in Table 1. Over one third of patients were
found to be elderly (Old or Oldest groups) and one third of elderly
patients were categorized in the Oldest group. There was no dif-
ference in gender distribution among the three age groups.
Notably, the severity of comorbidity rose with increasing age:
most patients in the Young group (78.6%, n = 2005) had a Deyo
Comorbidity Index score of 0 (no comorbidities), compared with
64.3% (n = 638) and 60.9% (n = 294) in the Old and Oldest
groups, respectively (P < 0.001). Interestingly, there was no sig-
nificant difference in the extent of operation among age groups.
Postoperative outcomes
There were 72 in-hospital postoperative mortalities, representing
1.8% of the whole study population. Rates of in-hospital mortal-
ity rose with increasing age from 1.3% (n = 34) in the Young
group, to 2.2% (n = 22) and 3.3% (n = 16) in the Old and Oldest
groups, respectively (P = 0.005). Non-home disposition was nec-
essary in 198 patients (4.9%) and rose significantly with increas-
ing age from 2.1% (n = 54) in the Young group to 6.1% (n = 59)
in the Old group and 18.3% (n = 85) in the Oldest group (P <
0.001). Although differences among age groups in median LoS
were statistically significant (P < 0.001), this was primarily driven
by range differences without clinical relevance. Overall, median
LoS was 6 days (range: 0–94 days). Bivariate analyses evaluating
the effect of extent of operation (wedge resection vs. lobectomy or
extended lobectomy) on each of these outcomes by age group are
also depicted in Table 2.
Independent predictors of outcome
After multivariate logistic regression analysis, two independent
predictors were identified for the outcome of postoperative
in-hospital mortality: age within the Oldest group (OR 2.21, 95%
CI 1.19–4.12; P < 0.001) and a Deyo score of3 (OR 6.95, 95% CI
3.55–13.60; P < 0.001). Table 3 lists the results of this analysis with
all included variables. Table 4 lists the results of the multivariate
analysis performed for poor transitional outcome. Increasing age
Table 1 Baseline patient demographics and type of surgery in the entire cohort and by age groupa
Characteristics All patients (n = 4026) Age group P-value
Young (< 65 years)
(n = 2551)
Old (65–74 years)
(n = 992)
Oldest ( 75 years)
(n = 483)
Gender, n (%) 0.160
Male 2092 (52.1%) 1297 (50.9%) 537 (54.2%) 258 (53.4%)
Female 1929 (48.0%) 1251 (49.1%) 453 (45.8%) 225 (46.6%)
Deyo Comorbidity Index score, n (%) < 0.001
0 2937 (73.0%) 2005 (78.6%) 638 (64.3%) 294 (60.9%)
1 793 (19.7%) 429 (16.8%) 239 (24.1%) 125 (25.9%)
2 181 (4.5%) 71 (2.8%) 68 (6.9%) 42 (8.7%)
 3 115 (2.9%) 46 (1.8%) 47 (4.7%) 22 (4.6%)
Surgery type, n (%) 0.570
Wedge resection 2663 (66.1%) 1686 (66.1%) 648 (65.3%) 329 (68.1%)
Lobectomy 1363 (33.9%) 865 (33.9%) 344 (34.7%) 154 (31.9%)
aColumns may not add to the total number for the group because some data for certain characteristics are missing. Elderly patients were more likely
to have higher comorbidity scores than younger patients, but were similar in other characteristics.
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(P < 0.001), increasing comorbidities (P < 0.001) and female
gender (P = 0.004) were all identified as independent predictors of
poor transitional outcome: age within the Old category, OR 2.44
(95% CI 1.66–3.58); age within the Oldest category, OR 8.48 (95%
CI 5.87–12.24); Deyo score of 1, OR 2.00 (95% CI 1.40–2.85);
Deyo score of 2, OR 4.70 (95% CI 2.93–7.56); Deyo score of 3,
OR 6.41 (95% CI 3.67–11.20), and female gender, OR 1.56 (95%
CI 1.15–2.11).
Discussion
Current population dynamics indicate that 20% of the population
in developed countries is expected to have passed the age of 65
years by 2025.16 In the USA, this segment of the population is
projected to double from 35 million in 2000 to >70 million by
2030.16 This demographic transition will result in an estimated
doubling of the number of new cancer diagnoses to 2.6 million
annually by 2050, with the most pronounced effect concerning the
Table 2 Postoperative outcomes following liver resection, by age group
Variable Age group P-value
Young (<65 years)
(n = 2551)
Old (65–74 years)
(n = 992)
Oldest ( 75 years)
(n = 483)
Length of stay, days, median (range)
All resections 6 (0–94) 7 (0–80) 7 (1–63) <0.001
Wedge resections 6 (0–94) 6 (0–80) 8 (1–63) <0.001
Hepatic lobectomy 6 (0–62) 7 (0–60) 7 (1–33) <0.001
In-hospital mortality, n (%)
All resections 34 (1.3%) 22 (2.2%) 16 (3.3%) 0.005
Wedge resections 18 (1.1%) 11 (1.7%) 11 (3.4%) 0.007
Hepatic lobectomy 16 (1.8%) 11 (3.2%) 5 (3.2%) 0.280
Non-home disposition, n (%)
All resections 54 (2.1%) 59 (6.1%) 85 (18.3%) <0.001
Wedge resections 37 (2.2%) 38 (6.0%) 54 (17.1%) <0.001
Hepatic lobectomy 17 (2.0%) 21 (6.3%) 31 (20.8%) <0.001
Length of stay after hepatectomy was slightly longer in elderly patients. Rates of in-hospital mortality and non-home disposition were significantly
higher in elderly patients.
Table 3 Multivariate analysis evaluating risk factors for in-hospital
mortality
Variable Odds ratio (95% CI) P-value
Age group <0.001
Young (< 65 years) Reference
Old (65–74 years) 1.40 (0.80–2.45)
Oldest ( 75 years) 2.21 (1.19–4.12)
Gender 0.051
Male Reference
Female 0.61 (0.37–1.00)
Deyo Comorbidity Index score <0.001
0 Reference
1 0.76 (0.38–1.53)
2 1.79 (0.74–4.33)
 3 6.95 (3.55–13.60)
Surgery type 0.070
Wedge resection Reference
Hepatic lobectomy 1.55 (0.97–2.50)
Increasing age and comorbidity were independent predictors of
in-hospital mortality.
95% CI, 95% confidence interval.
Table 4 Multivariate analysis evaluating risk factors for non-home
discharge
Variable Odds ratio (95% CI) P-value
Age group <0.001
Young (< 65 years) Reference
Old (65–74 years) 2.44 (1.66–3.58)
Oldest ( 75 years) 8.48 (5.87–12.24)
Gender 0.004
Male Reference
Female 1.56 (1.15–2.11)
Deyo Comorbidity Index score <0.001
0 Reference
1 2.00 (1.40–2.85)
2 4.70 (2.93–7.56)
 3 6.41 (3.67–11.20)
Surgery type 1.000
Wedge resection Reference
Hepatic lobectomy 1.00 (0.73–1.37)
Increasing age and comorbidity were independent predictors of non-
home discharge.
95% CI, 95% confidence interval.
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number of new gastrointestinal malignancies, including liver
metastases originating from colorectal cancers and other primary
sites.17,31 These changes will increase the number of elderly
patients requiring liver resection as part of their cancer treatment;
at present, these patients are often undertreated and liver resection
is avoided,19,20 limiting any curative potential for this population.
Although a series of studies have supported the safety of hepate-
ctomy in older adults,18,21–26,32–34 other studies have reported
contradictory results.35,36 Moreover, most studies evaluating
the role of liver resection in elderly patients derive from
single institutions,22–26,32–35,37 or have used heterogeneous
populations,26,27,32,33,35,37–40 thereby limiting their generalizability.
In addition, the potential impact of liver resection on elderly
patients in terms of postoperative recovery and quality of life
has not been studied, although it has important implications
for helping to delineate the role of hepatectomy in elderly
patients.
The goal of this study was to evaluate postoperative outcomes
(i.e. mortality) and transitional outcomes following liver resection
for metastatic disease in elderly patients using a nationwide data-
base. The analysis revealed that although postoperative mortality
is increased in older patients, it is still low and well within accept-
able ranges: the present analysis found a mortality rate of 3.3%
(n = 16) in patients aged75 years. Furthermore, on multivariate
analysis, the presence of multiple comorbidities (indicated by a
Deyo score of 3) was identified as the most important predictor
of postoperative mortality, and age was a significant predictor
only for patients aged 75 years. Conversely, in terms of transi-
tional outcomes, the need for postoperative transitional care was
found to be significantly greater in patients of increasing age,
reaching almost 20% (n = 85) in the oldest group of patients. After
multivariate analysis, in addition to female gender and comorbid-
ity status, age within the 65–74 years and 75 years groups were
both associated with an increased risk for postoperative transi-
tional care needs.
It is noteworthy that the postoperative mortality rate for older
patients found in this study was low and well within acceptable
ranges, and was similar to rates published for other younger popu-
lations.6,14,15,41 Previous reports evaluating postoperative mortality
in elderly patients have found rates in the range of 6–8%,26,32,37,38
significantly higher than the 3.3% rate observed in the oldest group
of patients (75 years) in this series; this discrepancy reflects a
number of differences among the studies. Firstly, the population
included in these studies differs from that in this report. In a study
by Chiappa et al.,32 the rate of post-hepatectomy mortality in 52
patients aged > 65 years was 8%; however, their population was
mixed and included patients with hepatocellular carcinoma and
cirrhosis. Similarly, Koperna and colleagues37 found a significantly
increased risk for mortality in patients with primary liver tumours
with or without cirrhosis (23%) compared with those undergoing
liver resection for metastatic disease (2.5%). Secondly, many of the
studies reporting higher mortality rates have generally focused on
elderly patients undergoing extensive resections or have identified
major liver resections as an important predictor of mortality.35,37,38
The present study found no difference in the distribution of more
extensive resections based on age and, additionally, did not identify
more extensive resection as a predictor of mortality. This difference
may also reflect the inclusion of heterogeneous populations in
published reports, for which postoperative outcomes are strongly
linked to the liver remnant (and, hence, the extent of resection),
particularly in the setting of cirrhosis. The lower mortality rate
observed in the elderly population in the present study reflects, in
part, a more homogeneous, low-risk group of patients (metastatic
disease only) and is similar to those reported by other studies that
have also limited analysis to elderly patients with metastatic disease
alone.12,18,23,34 The results of the present study emphasize the need
for more homogeneous comparisons when future studies evaluat-
ing other aspects of liver resection in elderly patients are
considered.
In the present series, a Deyo Comorbidity Index score of 3
was found to be the primary predictor of postoperative mortality
and was associated with a seven-fold increase in risk for death
following liver resection. This is an important finding, given the
increasing number of comorbidities observed in older patients,
and clarifies the association between mortality and increasing age
in a select group of older patients (those with multiple comor-
bidities). These findings are congruent with other reports in
which comorbidities have been associated with increased risk for
postoperative mortality.38–40 These studies are limited, however, by
the use of non-standardized or less reliable measures of comor-
bidity. The utilization of a standardized and dependable approach
to measuring the degree of comorbidities in the present study (the
Deyo modification of the Charlson Comorbidity Index) strength-
ens the validity of this association.
After multivariate analysis, age of 75 years was also found to
be an independent predictor of mortality. Two different age cut-
offs were used to discriminate elderly patients, according to pre-
vious reports42,43 and the authors’ own experiences, based on the
different overall physiological reserves of and clinical outcomes
in younger elderly patients (aged 65–74 years) compared with
the oldest patients (75 years). The present findings support the
authors’ experiences and previous reports in that the patients in
the Oldest group were found to have a higher risk for postop-
erative mortality (OR 2.21, 95% CI 1.19–4.12). However, the
overall low postoperative mortality rate observed in this high-
risk group supports the use of liver resection in these patients
when they are appropriately selected. Based on the findings of
this study, it appears clear that comorbidity is an important
factor in the selection process; however, future studies should
focus on the role of more comprehensive geriatric assessments to
better discriminate among those who will and will not benefit
from liver resection.
This study also evaluated the effects of age on need for transi-
tional care. Few studies have examined patient-centred outcomes
such as recovery to premorbid status (i.e. transitional outcomes)
and quality of life following surgery for liver metastases, although
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these are particularly relevant to elderly patients. A discharge des-
tination other than home was used as a surrogate for transitional
care needs and found to be directly related to increasing age; only
2.1% (n = 54) of patients in the Young group required transitional
care, compared with 6.1% (n = 59) and 18.3% (n = 85) of patients
in the Old and Oldest groups, respectively. More importantly, after
multivariate analysis, in addition to female gender and increasing
comorbidity, age in the 65–74 years category and 75 years cat-
egory were both associated with a significant increase in need for
transitional care [OR 2.44 (95% CI 1.66–3.58) and OR 8.48 (95%
CI 5.87–12.24), respectively]. This finding adds to available data
on postoperative transitional outcomes following liver resection
in elderly patients. A recent study by Cho and colleagues27
reported an important difference in rates of non-home discharge
between young and older patients (1% vs. 19%, respectively).
However, the study was limited by its inclusion of only rehabili-
tation facilities, the mixed nature of its population (primary and
metastatic disease) and its failure to evaluate other potential con-
founding factors. Despite this, the authors27 reported a high rate of
transitional care needs in elderly patients, as in the present study.
This has important implications when liver resection is offered to
elderly patients; in addition to longterm survival, transitional and
health-related quality of life outcomes should be included in the
process of deciding whether or not hepatectomy should be per-
formed, and patients should be counselled with regard to these
potential needs. If liver resection is deemed to be appropriate
following these standards, discharge planning should be coordi-
nated early during the preoperative period in high-risk
populations.
The findings of this study should be interpreted within the
scope of its limitations. Its retrospective nature has important
implications with regard to the selection bias associated with the
cohort and limits its ability to contribute towards the defining of
a standardized approach to selecting elderly patients who are
likely to withstand and benefit from liver resection. However,
high-risk groups were identified among those already selected for
liver resection, and this information can be used in the process of
decision making on liver resection for metastatic disease. Simi-
larly, the administrative nature of the NIS database prevents it
from capturing and adjusting for important perioperative clinical
factors, and thus limits the ability to examine other important
factors, such as the distribution of liver metastases, the number of
segments resected and the development of postoperative compli-
cations. In addition, as the NIS includes information on indi-
vidual hospital stays only, it lacks information on treatments
received prior to the hospital stay, such as chemotherapy, as well as
follow-up data, such as 60-day postoperative mortality and long-
term survival. However, the goal of the study was to examine the
association of age with mortality and need for transitional care on
a broader scale; the utilization of a population-level analysis with
a large sample, although limited by less detailed information,
strengthens the validity of the associations found in this study and
makes them more generalizable to different practices. Prospective
collaborative studies and the use of systematic approaches to
review published data will further enhance the ability to use more
detailed information and improve the selection process when
elderly patients with metastatic disease are considered for liver
resection.
In conclusion, this study demonstrates that liver resection in
well-selected elderly patients with metastatic disease is safe and
associated with a low risk for mortality, even in patients within the
oldest segment of the population (aged 75 years). The number
and degree of comorbidities are the most important indicators of
risk for mortality and should be assessed thoroughly when elderly
patients are considered for liver resection. The risk for mortality
should not cause liver resection to be withheld from elderly
patients on the grounds of age alone because appropriately
selected elderly patients can be expected to achieve good out-
comes following hepatectomy. Conversely, elderly patients in
general (aged 65 years) are more likely to require transitional
care following hepatectomy for metastatic disease. Based on these
findings, although hepatic resection can be considered to be safe
in well-selected elderly patients, nearly one in five elderly patients
are unable to regain their preoperative level of independence.
Patients should be counselled in this regard and efforts to antici-
pate transitional care needs must be incorporated into the treat-
ment pathway. Future studies should focus on establishing
standardized approaches for selecting elderly patients who are
likely to benefit from liver resection with regard to both postop-
erative outcomes (i.e. mortality) and patient-centred outcomes
(including the recovery of premorbid health and subsequent
quality of life), and on incorporating these outcomes into the
decision-making process when liver resection in an elderly patient
is considered.
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